Spotlight: Building for the long game: What it really takes to industrialise cell & gene therapy at scale

Why the old production model breaks: What Roche learned about the limits of legacy CGT manufacturing cost, throughput, flexibility and why incremental upgrades were no longer enough.

Inside Penzberg: designing for 2030, not today: What ‘state of the art’ actually means in practice for a future-facing gene therapy and diagnostics production centre and how facility design decisions strengthen resilience and value chains across Europe.

Cost isn’t just efficiency it’s architecture: How advanced facilities change the cost curve of CGT production, from automation and digitalisation to scale, standardisation and multi-product flexibility.

Collaboration as infrastructure, not outsourcing: Lessons from structuring partnerships, funding criteria and internal alignment - what Roche looked for, what didn’t work, and what they would do differently next time.

What this unlocks for the ecosystem: How facilities like this shift what’s possible for developers, partners and patients and what smaller companies should take away now when planning their own manufacturing strategies.